Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgery Today
Published in: Surgery Today 7/2014

01-07-2014 | Original Article

Pancreatic cancer in the remnant pancreas following primary pancreatic resection

Authors: Daisuke Hashimoto, Akira Chikamoto, Masaki Ohmuraya, Kazuya Sakata, Keisuke Miyake, Hideyuki Kuroki, Masayuki Watanabe, Toru Beppu, Masahiko Hirota, Hideo Baba

Published in: Surgery Today | Issue 7/2014

Login to get access

Abstract

Purpose

To clarify the clinical features of cancer in the pancreatic remnant.

Methods

We retrospectively reviewed the clinical and pathological findings of 10 patients who developed remnant pancreatic cancer in our hospital between 2002 and 2012. The KRAS sequences in both the initial pancreatic tumor and remnant pancreatic cancer were examined in two patients.

Results

Eight patients underwent a second pancreatectomy for remnant pancreatic cancer (resected group), while two patients were not operated on and underwent chemotherapy (unresected group). The remnant pancreatic cancer developed at the cut end of the pancreas (pancreaticogastrostomy site) in four patients. In the resected group, four patients died 17 months after the emergence of the remnant pancreatic cancer and four patients survived during the median 40.5-month observation period. The median survival of the unresected group after the emergence of the remnant pancreatic cancer was 10 months. The findings of the KRAS sequencing and immunohistological staining of the remnant pancreatic cancer for MUC1 and MUC2 in the two patients were consistent with those of the initial pancreatic tumor in one patient, and not consistent in the other.

Conclusions

Our results suggest that both local recurrence and a new primary cancer can develop in the pancreatic remnant, and repeated pancreatectomy can prolong survival.
Literature
1.
DeOliveira M, Winter J, Schafer M, Cunningham S, Cameron J, Yeo C, et al. Assessment of complications after pancreatic surgery a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg. 2006;244:931–9.PubMedCentralPubMedCrossRef
2.
Hashimoto D, Takamori H, Sakamoto Y, Ikuta Y, Nakahara O, Furuhashi S, et al. Is Estimation of physiologic ability and surgical stress (E-PASS) able to predict operative morbidity after pancreaticoduodenectomy? J Hepatobiliary Pancreat Surg. 2010;17:132–8.CrossRef
3.
Hashimoto D, Takamori H, Sakamoto Y, Tanaka H, Hirota M, Baba H. Can the Estimation of Physiologic Ability and SurgicalStress (E-PASS) scoring system predict operative morbidity after distal pancreatectomy? Surg Today. 2010;40:632–7.PubMedCrossRef
4.
Lin JW, Cameron JL, Yeo CJ, Riall TS, Lillemoe KD. Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg. 2004;8:951–9.PubMedCrossRef
5.
Hawkins WG, Alseidi A. DISPACT trial: what do we learn from equivalency? Lancet. 2011;377:1470–1.PubMedCrossRef
6.
Motoi F, Egawa S, Rikiyama T, Katayose Y, Unno M. Randomized clinical trial of external stent drainage of the pancreatic duct to reduce postoperative pancreatic fistula after pancreaticojejunostomy. Br J Surg. 2012;99:524–31.PubMedCrossRef
7.
Yamada S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, et al. Surgical results of pancreatoduodenectomy in elderly patients. Surg Today. 2012;42:857–62.PubMedCrossRef
8.
Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP. 2008;9:99–132.PubMed
9.
Smeenk HG, Incrocci L, Kazemier G, van Dekken H, Tran KT, Jeekel J, et al. Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. Dig Surg. 2005;22:321–8.PubMedCrossRef
10.
Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg. 2005;390:94–103.PubMedCrossRef
11.
Westerdahl J, Andrén-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer—local or hepatic? Hepatogastroenterology. 1993;40:384–7.PubMed
12.
Inoue K, Kosuge T, Shimada K, Yamamoto J, Takayama T, Ozaki H, et al. Repeated radical resection and intraoperative irradiation for recurrent pancreatic ductal adenocarcinoma after pancreatoduodenectomy. Surgery. 1995;118:909–11.PubMedCrossRef
13.
14.
Miura F, Takada T, Amano H, Yoshida M, Isaka T, Toyota N, et al. Repeated pancreatectomy after pancreatoduodenectomy. J Gastrointest Surg. 2007;11:179–86.PubMedCrossRef
15.
Cheng Q, Zhang B, Zhang Y, Jiang X, Zhang B, Yi B, et al. Predictive factors for complications after pancreaticoduodenectomy. J Surg Res. 2007;139:22–9.PubMedCrossRef
16.
House M, Fong Y, Arnaoutakis D, Sharma R, Winston C, Protic M, et al. Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. J Gastrointest Surg. 2008;12:270–8.PubMedCrossRef
17.
Japan Pancreas Society General rules for the study of pancreatic cancer (the 6th edition) April 2009.
18.
Japanese society of biliary surgery Society General rules for surgical and pathological studies on cancer of the biliary tract (the 5th edition) September 2003.
19.
20.
Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143:545–54.PubMedCentralPubMed
21.
Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549–54.PubMedCrossRef
22.
Zhang C, Guo W, Wu J, Song B, Zhang C, Dai Q, et al. Differential high-resolution melting analysis for the detection of K-ras codons 12 and 13 mutations in pancreatic cancer. Pancreas. 2011;40:1283–8.PubMedCrossRef
23.
Capella G, Cronauer-Mitra S, Pienado MA, Perucho M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect. 1991;93:125–31.PubMedCentralPubMedCrossRef
24.
Shigaki H, Baba Y, Watanabe M, Miyake K, Murata A, Iwagami S et al.KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: Pyrosequencing technology and literature review. Ann Surg Oncol. doi:10.​1245/​s10434-012-2819-z 2012 Dec 30. [Epub ahead of print].
25.
Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005;7:413–21.PubMedCentralPubMedCrossRef
26.
27.
Kobayashi T, Sato Y, Hirukawa H, Soeno M, Shimoda T, Matsuoka H, et al. Total pancreatectomy combined with partial pancreas autotransplantation for recurrent pancreatic cancer: a case report. Transplant Proc. 2012;44:1176–9.PubMedCrossRef
28.
Kim C, Tono T, Kimura Y, Watanabe A, Nakamura H, Inadome J, et al. Re-resection for local recurrence in the remnant pancreas after pancreaticoduodenectomy for pancreatic cancer- a case report. Gan To Kagaku Ryoho. 2011;38:2448–50.PubMed
29.
Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Fukutomi A, Sugimori K, et al. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol. 2011;29(suppl):4007.
30.
Ohashi Y, Tanaka M, Boku N, Ueno H, Okusaka T. Quality of life (QOL) evaluation within a randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable, advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol. 2011;29(suppl):9070.
31.
Yang SH, Dou KF, Sharma N, Song WJ. The methods of reconstruction of pancreatic digestive continuity after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. World J Surg. 2011;35:2290–7.PubMedCrossRef
Metadata
Title
Pancreatic cancer in the remnant pancreas following primary pancreatic resection
Authors
Daisuke Hashimoto
Akira Chikamoto
Masaki Ohmuraya
Kazuya Sakata
Keisuke Miyake
Hideyuki Kuroki
Masayuki Watanabe
Toru Beppu
Masahiko Hirota
Hideo Baba
Publication date
01-07-2014
Publisher
Springer Japan
Published in
Surgery Today / Issue 7/2014
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-013-0708-0

Other articles of this Issue 7/2014

Surgery Today 7/2014 Go to the issue

Short Communication

External sphincter resection for lower rectal and anal canal adenocarcinoma: achieving anal preservation with oncological and functional satisfaction

Review Article

Pancreaticodigestive anastomosis and the postoperative management strategies to prevent postoperative pancreatic fistula formation after pancreaticoduodenectomy

Original Article

Interim report of the Japanese original donor evaluation and management system: the medical consultant system

Review Article

Diagnostic imaging in the preoperative management of lung cancer

Case Report

Curative resection of hilar cholangiocarcinoma in a 25-year-old woman: report of a case

Case Report

Lesser omental hernia after total colectomy: report of a case